Topics

Nektar withdraws application for opioid painkiller after FDA panel's vote

23:54 EST 14 Jan 2020 | Reuters

Nektar Therapeutics said on Tuesday it was withdrawing the application for its opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration (FDA) panel unanimously voted against the drug's approval.

Original Article: Nektar withdraws application for opioid painkiller after FDA panel's vote

NEXT ARTICLE

More From BioPortfolio on "Nektar withdraws application for opioid painkiller after FDA panel's vote"

Quick Search

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...